Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
We will use the latest Rome IV criteria to recruit IBS-D patients and evaluate the effects of
repeated treatment with rifaximin and sequential treatment with rifaximin and probiotics on
different symptoms and quality of life. High-throughput sequencing combined with real-time
quantitative PCR will be used to comprehensively analyze the effects of different drugs on
intestinal flora. The study has important guiding significance for the treatment of patients
with IBS-D.
Phase:
Phase 4
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
First Affiliated Hospital of Wenzhou Medical University Peking Union Medical College Hospital RenJi Hospital Sir Run Run Shaw Hospital The Central Hospital of Lishui City The First Affiliated Hospital of Zhejiang Chinese Medical University